Methylselenol producing selenocompounds enhance the efficiency of mammaglobin‑A peptide vaccination against breast cancer cells

Babaer,Duaa; Zheng,Mu; Ivy,Michael  T.; Zent,Roy; Tiriveedhi,Venkataswarup

doi:10.3892/ol.2019.11010

Methylselenol producing selenocompounds enhance the efficiency of mammaglobin‑A peptide vaccination against breast cancer cells

Authors:
- Duaa Babaer
- Mu Zheng
- Michael T. Ivy
- Roy Zent
- Venkataswarup Tiriveedhi
View Affiliations

Affiliations: Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA, Department of Chemistry, Tennessee State University, Nashville, TN 37209, USA, Department of Medicine, Cell and Developmental Biology, Vanderbilt University School of Medicine, Veterans Affairs Medical Center, Vanderbilt University, Nashville, TN 37212, USA
Published online on: October 18, 2019 https://doi.org/10.3892/ol.2019.11010
Pages: 6891-6898

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous phase I DNA‑vaccine based clinical trials using Mammaglobin‑A (Mam‑A), a human breast tumor associated antigen (TAA), demonstrated that this agent was safe and efficient at treating patients with stage IV breast cancer. The long‑term success of cancer vaccines is limited by the diminished expression of human leukocyte antigen (HLA) class I molecules in the tumor microenvironment. The current study assessed the impact of various selenocompounds on the expression of HLA class I molecules in THP‑1 cells, an apparent proficient antigen that presents a human monocyte‑like cell line, and their eventual activation of MamA2.1 (HLA‑A2 immunodominant epitope of Mam‑A) specific cytotoxic CD8+ T lymphocytes (CTLs). The results revealed that, following treatment with methylselenol producing compounds [methylselenic acid (MSA) and dimethylselenide (DMDSe)], the expression of HLA class‑I was increased and components involved with the antigen presentation machinery of THP‑1 cells were upregulated. Furthermore, CTLs activated by MamA2.1 peptide presenting THP‑1 cells, pre‑treated with MSA and DMDSe, demonstrated an enhanced cytotoxicity in HLA‑A2+/Mam‑A+ AU565 and UACC‑812 breast cancer cell lines when compared with CTLs activated by THP‑1 cells without drug treatment. However, no significant cytotoxicity was observed under similar conditions in HLA‑A2+/Mam‑A‑ MCF‑7 and MDA‑MB‑231 breast cancer cell lines. The results indicated that treatment with methylselenol producing compounds retained antigen‑dependent activation of CD8+ T cells. The data of the current study demonstrated that MSA and DMDSe potentiated effector cytotoxic responses following TAA specific activation of CTLs, indicating their future role as vaccine adjuvants in cancer immunotherapy.

View Figures

View References

1	Beatty GL and Gladney WL: Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 21:687–692. 2015. View Article : Google Scholar : PubMed/NCBI
2	Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, Shinchi H, Koriyama C, Ueno S, Yoshinaka H and Natsugoe S: Clinical implication of HLA class I expression in breast cancer. BMC Cancer. 11:4542011. View Article : Google Scholar : PubMed/NCBI
4	Zeng H and Combs GF Jr: Selenium as an anticancer nutrient: Roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 19:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
5	Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 276:1957–1963. 1996. View Article : Google Scholar : PubMed/NCBI
6	Ip C, Thompson HJ, Zhu Z and Ganther HE: In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 60:2882–2886. 2000.PubMed/NCBI
7	Suzuki KT, Kurasaki K and Suzuki N: Selenocysteine beta-lyase and methylselenol demethylase in the metabolism of Se-methylated selenocompounds into selenide. Biochim Biophys Acta. 1770:1053–1061. 2007. View Article : Google Scholar : PubMed/NCBI
8	Qi Y, Fu X, Xiong Z, Zhang H, Hill SM, Rowan BG and Dong Y: Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One. 7:e315392012. View Article : Google Scholar : PubMed/NCBI
9	Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, et al: A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2:823–842. 2010. View Article : Google Scholar : PubMed/NCBI
10	Mikhitarian K, Gillanders WE, Almeida JS, Hebert Martin R, Varela JC, Metcalf JS, Cole DJ and Mitas M: An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. Clin Cancer Res. 11:3697–3704. 2005. View Article : Google Scholar : PubMed/NCBI
11	Fleming TP and Watson MA: Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann NY Acad Sci. 923:78–89. 2000. View Article : Google Scholar : PubMed/NCBI
12	Goedegebuure PS, Watson MA, Viehl CT and Fleming TP: Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets. 4:531–542. 2004. View Article : Google Scholar : PubMed/NCBI
13	Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM, et al: Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: An interim analysis of a prospective multi-institutional cohort study. Ann Surg. 239:828–840. 2004. View Article : Google Scholar : PubMed/NCBI
14	Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR and Mohanakumar T: Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8⁺ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat. 88:29–41. 2004. View Article : Google Scholar : PubMed/NCBI
15	Bharat A, Benshoff N, Fleming TP, Dietz JR, Gillanders WE and Mohanakumar T: Characterization of the role of CD8⁺ T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers. Breast Cancer Res Treat. 110:453–463. 2008. View Article : Google Scholar : PubMed/NCBI
16	Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, et al: Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res. 20:5964–5975. 2014. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Cai Z, Dong L, Song C, Zhang Y, Zhu C, Zhang Y, Ling Q, Hoffmann PR, Li J, Huang Z and Li W: Methylseleninic acid provided at nutritional selenium levels inhibits angiogenesis by down-regulating integrin beta3 signaling. Sci Rep. 7:94452017. View Article : Google Scholar : PubMed/NCBI
19	Hagemann-Jensen M, Uhlenbrock F, Kehlet S, Andresen L, Gabel-Jensen C, Ellgaard L, Gammelgaard B and Skov S: The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D. J Biol Chem. 289:31576–31590. 2014. View Article : Google Scholar : PubMed/NCBI
20	Amara S and Tiriveedhi V: The five immune forces impacting DNA-based cancer immunotherapeutic strategy. Int J Mol Sci. 18:E6502017. View Article : Google Scholar : PubMed/NCBI
21	Slingluff CL Jr: The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination? Cancer J. 17:343–350. 2011. View Article : Google Scholar : PubMed/NCBI
22	Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE and Mohanakumar T: Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4⁺ ICOShi T cells. Breast Cancer Res Treat. 138:109–118. 2013. View Article : Google Scholar : PubMed/NCBI
23	Dunn GP, Old LJ and Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360. 2004. View Article : Google Scholar : PubMed/NCBI
24	Matsunaga Y, Fukuma D, Hirata S, Fukushima S, Haruta M, Ikeda T, Negishi I, Nishimura Y and Senju S: Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells. J Immunol. 181:6635–6643. 2008. View Article : Google Scholar : PubMed/NCBI
25	Buonaguro L, Petrizzo A, Tornesello ML and Buonaguro FM: Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol. 18:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
26	Bhat P, Leggatt G, Waterhouse N and Frazer IH: Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 8:e28362017. View Article : Google Scholar : PubMed/NCBI